The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Congress 2022 | JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
Alison Moliterno, MD, Johns Hopkins Medicine, Baltimore, MD, discusses the association between JAK2 V617F variant allele fraction (VAF), clinical phenotype, and venous thrombosis risk in patients with polycythemia vera (PV), discussing its role as a prognostic and diagnostic marker in this disease. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting with Pharmessentia and Protagonist
